Press Releases Ypsomed Group

Burgdorf - The guidance of CHF 60 million EBIT for the 2017/18 financial year announced in November 2017 remains unchanged. Ypsomed is investing in its global expansion and the establishment of new subsidiaries for the insulin pump business. Ypsomed expects sustained growth in the Ypsomed Delivery Systems (YDS) segment.

Press Releases Ypsomed Group

Burgdorf - During the first six months of the business year 2017/18, Ypsomed generated a consolidated total turnover of CHF 213.4 million. The growth corresponds to an increase in turnover of 15.1% (previous year: CHF 185.4 million). The net profit for the reporting period amounts to CHF 23.4 million (previous year CHF 22.4 million). The operating result amounts to CHF 26.9 million with an EBIT margin of 12.9 %. Ypsomed expects a growth in turnover of approximately 18% versus the presently forecast 15% and increases the forecast to an operating result of around CHF 60 million for the business year 2017/18.

Press Releases Ypsomed Group

Burgdorf – Hanmi Pharmaceutical Co., Ltd. has three biotechnology proteins in its project portfolio that are in various stages of development and approval.

Press Releases Ypsomed Group

Burgdorf – Austrian specialist pharmaceutical company, Ever Pharma, now offers the D-mine Pen for the treatment of Parkinson patients with apomorphine. This reusable pen, which is based on the Ypsomed ServoPen platform, facilitates subcutaneous administration with its patient friendly design.

Press Releases Ypsomed Group

Burgdorf – On 26th September 2017, groundbreaking took place for Ypsomed’s new production facility in the Industrial Park of Schwerin, Germany. Ypsomed is to invest over EUR 100 million in the new production site. Production will commence during the first half of 2019. Ypsomed plans to create roughly 150 jobs in the region over the next five years.